Vistagen Therapeutics, Inc. Common Stock VTGN

$0.27 +0.49% at last close

Analyst Consensus

Consensus Rating
Hold (0 Buy · 3 Hold · 0 Sell)
Average Price Target
$0.90
Implied Upside
+236.3%
Price Target Range
$0.90 – $0.90
Analysts (12 mo)
3

Recent Analyst Actions

DateFirmActionRatingPrice Target
2025-12-17
William BlairTim Lugo
 Downgrades Outperform → Market perform —
2025-12-17
Maxim GroupJason McCarthy
 Downgrades Buy → Hold —
2025-12-17
JefferiesAndrew Tsai
 Downgrades Buy → Hold $15 → $1
2023-12-07
JefferiesAndrew Tsai
 Upgrades Hold → Buy $0 → $15
2023-11-14
StifelPaul Matteis
 Initiates coverage on Buy $12
2023-09-05
Maxim GroupJason McCarthy
 Maintains Buy $30
2023-08-07
Maxim GroupJason McCarthy
 Upgrades Hold → Buy $30
2022-07-26
Maxim GroupJason McCarthy
 Downgrades Buy → Hold —
2022-07-22
William BlairTim Lugo
 Downgrades Outperform → Market perform —
2021-05-20
BairdBrian Skorney
 Initiates coverage on Outperform $270
2021-02-18
JefferiesAndrew Tsai
 Initiates coverage on Buy $180
2021-01-04
William BlairTim Lugo
 Upgrades Market perform → Outperform —
2020-10-08
Aegis CapitalNathan Weinstein
 Initiates coverage on Buy $180
2019-08-28
William BlairTim Lugo
 Initiates coverage on Outperform —
2019-07-22
Chardan Capital
 Downgrades Buy → Neutral $660 → $21
2018-06-27
Maxim GroupJason McCarthy
 Initiates coverage on Buy $180
2018-05-24
Oppenheimer
 Initiates coverage on Outperform $180

Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.

Key Stats

Last Close
$0.27
Market Cap
$11.88 million
52-Week Range
$0.20 – $5.14
Average Volume
5.36 million shs

Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.